Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. antigen presentation
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads

Refine by
Date

  • Older

Antigen Presentation Articles & Analysis

30 news found

Protheragen Announces Vaccine Development Services Targeting Rare Infectious Diseases

Protheragen Announces Vaccine Development Services Targeting Rare Infectious Diseases

Protheragen focuses on delivering comprehensive vaccine development services, specifically designed to meet the distinct challenges presented by various pathogens. With advanced research equipment and an excellent expert team, the company can develop vaccines targeting different types of pathogens, including bacterial infections, fungal infections, viral infections, prion ...

ByProtheragen


Alfa Chemistry-A New Supplier of Vaccine Excipients, Nucleic Acid Delivery Excipients and SARS-CoV-2 Detection Raw Materials

Alfa Chemistry-A New Supplier of Vaccine Excipients, Nucleic Acid Delivery Excipients and SARS-CoV-2 Detection Raw Materials

The featured vaccine products supplied by Alfa Chemistry are listed as below: Nucleic Acid Delivery ExcipientsNucleotide vaccines, including mRNA vaccines with their intracellular antigen synthesis, have been shown to be potent activators of a cytotoxic immune response. However, the intracellular delivery of mRNA vaccines to the cytosol of antigen ...

ByAlfa Chemistry


CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service

CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service

The Product Manager of the Long-Read Sequencing Division announced the launch of the Human Leukocyte Antigen (HLA) Typing service to support high-resolution HLA typing in a rapid and cost-efficient manner. ...

ByCD Genomics


Beyond Cancer Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases

Beyond Cancer Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases

“By locally ablating tumors with UNO we have shown that the recruitment of antigen-presenting cells (APCs) triggers T-cells to proliferate and mature, producing a long-term systemic immune response that reduces distant metastases and prolongs survival in ...

ByBeyond Air Inc


Engineering antibody-antigen interfaces to improve therapeutic properties

Engineering antibody-antigen interfaces to improve therapeutic properties

A case for antibody engineering B cells produce antibodies in response to the presence of antigens. These antibodies then recognize and bind to antigens, triggering one of several downstream activities, such as: Neutralization by alteration of the chemical composition of an antigen Immobilization of the ...

ByCresset Group


AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate

AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate

IRVINE, Calif. – AUG. 29, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel. The results were published in the article ...

ByAIVITA Biomedical, Inc.


Taiwan Vaccine Adjuvant Pioneer ImmunAdd to Attend 2022 BIO International Convention in San Diego

Taiwan Vaccine Adjuvant Pioneer ImmunAdd to Attend 2022 BIO International Convention in San Diego

IA-05 is a fully synthetic small molecule which that, in head-to-head preclinical studies against vaccines incorporating several existing adjuvants, including QS-21, demonstrated improved cross-presentation of antigens and well tolerability. Currently, QS-21-incorporated vaccines have shown better protection against virus infection. ...

ByImmunadd, Inc.


ANGANY Gaining Momentum for Plant-Based Immunotherapy Platform

ANGANY Gaining Momentum for Plant-Based Immunotherapy Platform

Canadian biotechnology company ANGANY (www.ANGANY.com) is presenting its immunotherapy platform at BIO International Convention, a critical rendez-vous for the global pharmaceutical industry which takes place in San Diego, California between June 13th and 16th. ...

ByAngany Inc.


Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

Ex vivo studies show that treatment with IO-108 produces pro-inflammatory activity and an enhanced antigen-presenting cell (APC) phenotype to multiple stimuli, including T cell activators, and STING and TLR agonists. ...

ByImmune-Onc Therapeutics, Inc.


Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

“Clinical data previously collected by Cancer Research UK demonstrated peripheral immunogenicity in patients with NSCLC treated with VAC2, providing support to the underlying mechanism of using allogeneic dendritic cells to present tumor-associated antigens to the body’s immune system. Simultaneous with Cancer Research UK efforts to complete ...

ByLineage Cell Therapeutics, Inc.


Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors

Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors

ABOUT LILRB4 (also known as ILT3) LILRB4, also known as ILT3, is an immune inhibitory transmembrane receptor expressed by monocytic myeloid cells, including dendritic cells, monocytes, monocytic myeloid-derived suppressor cells and tumor-associated macrophages. LILRB4 inhibits antigen-presenting cell function, resulting in immune tolerance. LILRB4 is also ...

ByImmune-Onc Therapeutics, Inc.


Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022

Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022

The abstract title has been posted to the AACR Online Itinerary Planner, will be published in the online Proceedings of the AACR, and is detailed below. The data to be presented demonstrate significantly greater anti-tumor activity of cytoTIL15 therapy in vivo compared to conventional TIL + IL2 therapy in a human leukocyte antigen (HLA)-matched, allogeneic ...

ByObsidian Therapeutics, Inc.


Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens

Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens

The newly introduced antigens consist of five of the most common staphylococcus aureus enterotoxins and are ideal for in vitro detection and diagnostic studies. ...

ByCreative Diagnostics


NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

The collaboration is centered around NexImmune’s artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. ...

ByNexImmune, Inc.


NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

VAXIMM’s plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target a wide range of cancer-related antigens. The platform allows for fast and scalable manufacturing of personalized T-cell cancer vaccines and may overcome key challenges ...

ByNEC OncoImmunity AS 


Update on Continued Research in Oncology

Update on Continued Research in Oncology

Based on the results of these studies and on further promising results presented in scientific literature, the company has decided to accelerate the development within the immuno-oncology field in two priority focus areas – therapeutic vaccines and vectors for “drug delivery”. As a first priority, Abera will conduct studies within the concept of therapeutic ...

ByAbera Bioscience AB


Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

It does this by delivering cancer-associated proteins — known as MAGE-A3 and NY-ESO-1 antigens — to antigen presenting cells (dendritic cells), causing the immune system to produce cytotoxic T cells which are able to target and kill cancer cells expressing these antigens. ...

ByVaccitech plc


New Data Suggest COVAXIN (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination

New Data Suggest COVAXIN (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination

“As a whole-virion inactivated vaccine, we anticipated COVAXIN™ would produce an immune response against multiple antigens present in the SARS-CoV-2 virus, such as spike and nucleoprotein antibodies,” said Shankar Musunuri, PhD, MBA, Chairman of the Board, Chief Executive Officer and Co-Founder of Ocugen. ...

ByOcugen, Inc.


Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine

Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine

The main goal of the vaccine is to elicit a strong and long-lasting immune response against tumor antigens by targeting class I and class II epitopes. These two types of responses have been established as key factors in driving a sustained anti-tumor response. ...

ByNEC OncoImmunity AS 


Creative Proteomics Upgraded Exosome Proteomics Service to Accelerate Biomarker Discovery Research

Creative Proteomics Upgraded Exosome Proteomics Service to Accelerate Biomarker Discovery Research

They can carry nucleic acids, proteins, lipids, etc., and are present in various body fluids such as blood, saliva, and urine. More and more studies have confirmed that exosomes can perform special functions by transferring specific substances such as nucleic acids, proteins, and lipids between cells. For example, it plays an important role in the process of ...

ByCreative Proteomics

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT